Compare Stocks

Apollo Tactical Income Fund Inc. is a closed-ended fixed income fund launched and managed by Apollo Credit Management, LLC. The fund invests in fixed income markets. It primarily invests in senior secured loans including floating rate senior loans, high yield corporate bonds, and other credit instruments of varying maturities made to companies whose debt is typically rated below investment grade. The fund employs a conservative approach to credit selection that focuses on such factors as collateral coverage, structural seniority, credit fundamentals, with emphasis on leading defensible market positions, stable companies with positive cash flow, and proven management teams to create its portfolio. Apollo Tactical Income Fund Inc. was formed on February 25, 2013 and is domiciled in the United States.

Capstone Companies, Inc., through its subsidiaries, engages in the development, marketing, and sale of consumer home light-emitting diode (LED) lighting products for indoor and outdoor applications worldwide. Its lighting products include connected surfacessmart mirrors and standard rectangular wardrobe/fitness mirrors. The company markets its products under the Capstone Lighting brand name, as well as under the Hoover Home LED brand through a network of direct sales force, retailers, and distributors. It sells its products through e-commerce websites. The company was formerly known as CHDT Corporation and changed its name to Capstone Companies, Inc. in June 2012. Capstone Companies, Inc. is headquartered in Deerfield Beach, Florida.

The FT Cboe Vest U.S. Equity Deep Buffer ETF - January (DJAN) is an exchange-traded fund that is based on the SPDR S&P 500 ETF Trust index. The fund aims for specific buffered losses and capped gains on SPY ETF over a specific holdings period. The actively-managed fund holds options and collateral. DJAN was launched on Jan 15, 2021 and is managed by First Trust.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Lumenpulse Inc. is engaged in the design, development, assembly and sale of lighting products. The Company operates in two segments: Lumenpulse LED products (LP) and other manufacturers' products (OMP). The Company's LP segments' products consist of light-emitting diode (LED) lighting solutions. The Company's LP segment designs, manufactures and sells lighting fixtures and solutions for indoor and outdoor applications with its focus on the commercial, institutional and urban environment markets. Its OMP segment consists of products designed and manufactured by manufacturers other than the Company and can include both LED and traditional lighting fixtures. Its products include Lumenarea, Lumenalpha Downlights, Lumenbeam, Lumencove, Lumenline, Lumendome, Lumensub, Lumensign, Lumentask, Lumentube and Lumenedge. The Company develops its solutions by combining configurable LED fixtures with its control systems and patented control, binning, dimming and thermal management technologies.